Henry Schein Q4 Earnings Call Highlights

Core Insights - Henry Schein reported its highest sales growth in 15 quarters, with fourth-quarter global sales reaching $3.4 billion, up 7.7% year over year, driven by strong performance across various segments [2][4][6]. Financial Performance - The company reported a fourth-quarter GAAP operating margin of 4.76%, down 10 basis points from the prior year, while the non-GAAP operating margin was 7.42%, remaining relatively flat year over year [1]. - Fourth-quarter GAAP net income was $101 million, or $0.85 per diluted share, compared to $94 million, or $0.74 per diluted share, in the prior-year period. Non-GAAP net income was $160 million, or $1.34 per diluted share, up from $149 million, or $1.19 per diluted share [7]. - Adjusted EBITDA for the fourth quarter was $291 million, an increase from $270 million, representing an 8.4% growth [7]. Segment Performance - Global specialty products saw sales growth of 14.6%, driven by strong performance in implants and biomaterials, with double-digit growth in value implants [10]. - Global technology sales grew 8.4%, supported by practice management software and significant growth in Dentrix Ascend, which surpassed 11,000 subscribers [11]. - The global distribution and value-added services group delivered 7.0% sales growth, with U.S. dental merchandise sales growing by 3.6% and U.S. dental equipment sales growing by 10.6% [8][9]. Leadership Transition - Fred Lowery will officially join as CEO next week, with a focus on a 100-day "listening tour" to validate existing initiatives and engage with stakeholders [3][6]. - Stanley Bergman will remain as Chairman of the Board, emphasizing Lowery's experience in scaling businesses through acquisitions and organic growth [4][6]. Strategic Initiatives - The company expects over $200 million of operating income improvement through cost savings and incremental gross margin opportunities, with an annual run-rate improvement of over $125 million by the end of 2026 [13]. - Henry Schein repurchased 2.8 million shares for $200 million at an average price of $71.10 per share, ending the year with approximately $780 million remaining under its authorization [14]. 2026 Outlook - For 2026, Henry Schein guided to sales growth of 3% to 5% and non-GAAP diluted EPS of $5.23 to $5.37, representing 5% to 8% growth compared to 2025 [15]. - The guidance assumes stable dental and medical end markets and consistent foreign exchange rates [15][16].